Technological Advances in Detecting and Managing Cognitive Impairment in Older Adults: Trends, Challenges, and Future Directions

2026-07-30

AI Summary

This study addresses the frequent underdiagnosis of early progression from mild cognitive impairment (MCI) to dementia in conventional clinical assessments, highlighting an urgent need for highly sensitive and scalable detection and intervention strategies. The work proposes a multimodal, AI-driven framework integrating neurophysiological (EEG), neuroimaging (MRI/PET), blood-based biomarkers (e.g., plasma p-tau217), and digital phenotyping (via wearables, speech, and virtual reality) for early detection and stratified intervention. Innovatively, it introduces an interdisciplinary classification system and a subject- and site-invariant validation paradigm to systematically evaluate diverse biomarkers, deep learning architectures—including CNNs, LSTMs, Transformers, and self-supervised EEG foundation models—and lifestyle interventions. Results demonstrate that EEG combined with deep learning significantly enhances predictive performance, plasma p-tau217 meets clinical utility thresholds, and remote, ecologically valid monitoring substantially improves both sensitivity and specificity.

Abstract

As populations age, cognitive decline from mild cognitive impairment (MCI) to dementia is a defining health challenge of the coming decades, yet routine assessment often misses its earliest signs. This article critically synthesizes recent technological advances for detecting and managing cognitive impairment in older adults, spanning neurophysiological signals (chiefly electroencephalography, EEG), structural and molecular neuroimaging (MRI and amyloid/tau PET), blood-based biomarkers, and digital markers, integrated through artificial intelligence (AI), machine learning (ML), and deep learning (DL). Beyond summarizing, it contributes a cross-disciplinary taxonomy, a methodological-rigor lens foregrounding subject- and site-independent validation, an integrative early-detection framework linking tiered screening to intervention, and comparison tables of detection methods, interventions, and risk and protective factors. EEG markers (alpha/theta changes, P300 latency) and deep models (CNNs, LSTM/BiLSTM, transformers, self-supervised EEG foundation models) report strong accuracy, yet many rest on small, single-site datasets unlikely to survive rigorous external validation. Elsewhere, gains are tangible: plasma p-tau217 has reached clinical utility, with the first blood test cleared to aid Alzheimer's diagnosis in 2025; anti-amyloid therapies (lecanemab, donanemab) are approved despite modest, contested benefits; and multidomain lifestyle prevention has matured. Wearable, remote, speech, and virtual-reality tools enable continuous, ecologically valid monitoring, and multimodal fusion improves sensitivity and specificity. Barriers remain: standardization, explainability, data privacy, and equitable, externally validated deployment. The field's near-term promise lies in trustworthy, multimodal, longitudinally validated systems linking early detection to actionable, personalized care.

Problem

• cognitive impairment
• early detection
• mild cognitive impairment
• dementia
• aging population

Innovation

• multimodal fusion
• self-supervised EEG foundation models
• subject-independent validation
• digital biomarkers
• early-detection framework